Aardvark Therapeutics, Inc. (AARD)

Last Closing Price: 0.91 (2026-11-18)

Company Description

Aardvark Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The company's lead product candidate includes ARD-101. Aardvark Therapeutics Inc. is based in SAN DIEGO.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) --
Net Income (Most Recent Fiscal Year) $-57.59M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 0.44
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) --
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -89.27%
Return on Assets (Trailing 12 Months) -80.39%
Current Ratio (Most Recent Fiscal Quarter) 9.11
Quick Ratio (Most Recent Fiscal Quarter) 12.63
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $2.63
Earnings per Share (Most Recent Fiscal Quarter) $-0.88
Earnings per Share (Most Recent Fiscal Year) $-2.93
Diluted Earnings per Share (Trailing 12 Months) $-3.34
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 21.89M
Free Float 17.99M
Market Capitalization $25.17M
Average Volume (Last 20 Days) 1.74M
Beta (Past 60 Months) 4.38
Percentage Held By Insiders (Latest Annual Proxy Report) 17.80%
Percentage Held By Institutions (Latest 13F Reports) --
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%